SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Viking Therapeutics, Inc. (VKTX)

12 weeks from the last enrolled (July 12)

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
ZeWaffleBaron Member Profile
 
Followed By 7
Posts 174
Boards Moderated 0
Alias Born 04/26/17
160x600 placeholder
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/11/2017 4:26:56 PM
Viking Therapeutics Announces Closing of Public Offering of Common Stock "PR Newswire (US)" - 12/11/2017 4:15:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 12/7/2017 4:40:46 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/7/2017 6:04:54 AM
Viking Therapeutics Announces Pricing of $12.8 Million Public Offering of Common Stock "PR Newswire (US)" - 12/6/2017 8:08:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 12/5/2017 4:30:49 PM
Viking Therapeutics Announces Proposed Public Offering of Common Stock "PR Newswire (US)" - 12/5/2017 4:18:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/28/2017 7:08:18 AM
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture "PR Newswire (US)" - 11/28/2017 7:02:00 AM
Investor Expectations to Drive Momentum within Vector Group, NovoCure, ORBCOMM, Ecolab, Bank of America, and Viking Therapeut... "GlobeNewswire Inc." - 11/20/2017 8:20:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/8/2017 5:12:26 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/8/2017 4:13:01 PM
Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update "PR Newswire (US)" - 11/8/2017 4:05:00 PM
Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017 "PR Newswire (US)" - 11/1/2017 7:30:00 AM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 10/27/2017 6:02:23 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) "Edgar (US Regulatory)" - 10/26/2017 4:54:21 PM
Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at... "PR Newswire (US)" - 10/24/2017 7:05:00 AM
Viking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy ... "PR Newswire (US)" - 10/23/2017 7:05:00 AM
Securities Registration Statement (s-1) "Edgar (US Regulatory)" - 10/17/2017 4:49:11 PM
Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleuko... "PR Newswire (US)" - 10/4/2017 7:05:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 9/29/2017 4:46:11 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/29/2017 7:06:35 AM
Viking Therapeutics Announces Purchase Agreements for up to $16.25 Million with Lincoln Park Capital "PR Newswire (US)" - 9/29/2017 7:05:00 AM
Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settin... "PR Newswire (US)" - 9/25/2017 7:30:00 AM
Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatit... "PR Newswire (US)" - 9/11/2017 7:05:00 AM
ZeWaffleBaron   Thursday, 10/05/17 07:51:36 AM
Re: zoomlik post# 707
Post # of 1146 
12 weeks from the last enrolled (July 12) is actually Oct 4. This is top line data, dxa scan at 12 weeks. Not the full trial results. The meeting is scheduled at a completely reasonable time interval to be compatible with results. Not saying it will happen, but the timing is lined up well. They originally said 2-4 weeks possible to clean up data. This would be one week to clean data (that they've had forever to refine as the trial has progressed). You seem to be spreading misinformation

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist